# Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

> **NCT00321594** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 54 (actual)

## Conditions studied

- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Recurrent Adult Primary Liver Cancer

## Interventions

- **DRUG:** belinostat

## Key facts

- **NCT ID:** NCT00321594
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-08
- **Final completion:** 2012-10
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321594, "Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00321594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*